Health Care • Medical/Dental Instruments
$4.40 ▼ -0.84
(-16.03%)
MKT CAP: $13.9M • VOL: 48.3K
52W L $3 52W H $17
ROARABLE / RQD
E • 21/100
PIOTROSKI
3 / 9
CTSO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $37.1M | $35.6M | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $26.5M | $24.9M | — |
| Gross Margin % | 71.5% | 69.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$14.7M | -$16.5M | -$31.9M |
| Operating Margin % | -39.8% | -46.2% | — |
| Net Income (GAAP) | -$8.2M | -$20.7M | -$29.2M |
| EBITDA (Normalized) | -$14.6M | -$16.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$12.4M | -$14.4M | -$21.7M |
| Capital Expenditures (CapEx) | $164.0K | $284.0K | — |
| Free Cash Flow (FCF) | -$12.5M | -$14.7M | -$21.7M |
| FCF Margin % | -33.8% | -41.3% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $6.2M | $3.3M | — |
| Total Debt (Short + Long Term) | $16.7M | $14.0M | — |
| Total Stockholders' Equity | $5.9M | $11.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CTSO.